Activation of PI3K signaling in merkel cell carcinoma

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1227-1236

  Nardi, Valentina ^a   Song, Youngchul ^b   Santamaria Barria, Juan A ^a   Cosper, Arjola K ^b   Lam, Quynh ^a   Faber, Anthony C ^b   Boland, Genevieve M ^a   Yeap, Beow Y ^b,c   Bergethon, Kristin ^a   Scialabba, Vanessa L ^a   Tsao, Hensin ^a,c   Settleman, Jeffrey ^b,c   Ryan, David P ^b,c   Borger, Darrell R ^b,c   Bhan, Atul K ^a,c   Hoang, Mai P ^a,c   Iafrate, Anthony J ^a,c   Cusack, James C ^a,c   Engelman, Jeffrey A ^b,c   Dias Santagata, Dora ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; ARGININE; LYSINE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE; PHOSPHOINOSITIDE 3 KINASE CA GENE; PHOSPHOINOSITIDE 3 KINASE GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; TP53 GENE; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84863277615     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2308     Document Type: Article

References (56)

1. Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972;105:107-10.
2. Gould VE, Moll R, Moll I, Lee I, Franke WW. Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 1985;52:334-53. (Pubitemid 15056792)
3. Walsh NM. Primary neuroendocrine (Merkel cell) carcinoma of the skin: morphologic diversity and implications thereof. Hum Pathol 2001;32:680-9. (Pubitemid 32726892)
4. Smith PD, Patterson JW. Merkel cell carcinoma (neuroendocrine carcinoma of the skin). Am J Clin Pathol 2001;115(Suppl):S68-78.
5. TRMCCG. Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol 2009;27:4021-6.
6. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4. (Pubitemid 40075960)
7. Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 1998;339:1247-8. (Pubitemid 28482140)
8. Howard RA, Dores GM, Curtis RE, Anderson WF, Travis LB. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:1545-9. (Pubitemid 44299330)
9. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010;37:20-7.
10. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008;58:375-81. (Pubitemid 351226308)
11. Poulsen M. Merkel cell carcinoma of skin: diagnosis and management strategies. Drugs Aging 2005;22:219-29. (Pubitemid 40529888)
12. Wong HH, Wang J. Merkel cell carcinoma. Arch Pathol Lab Med 2010;134:1711-6.
13. Hanly AJ, Elgart GW, Jorda M, Smith J, Nadji M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000;27:118-20. (Pubitemid 30113780)
14. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-100. (Pubitemid 351300792)
15. Kassem A, Schopflin A, Diaz C, Weyers W, Stickeler E, Werner M, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 2008;68:5009-13.
16. Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, et al. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 2009;125:1250-6.
17. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009;5:e1000363.
18. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A 2008;105:16272-7.
19. Sastre-Garau X, Peter M, Avril MF, Laude H, Couturier J, Rozenberg F, et al. Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol 2009;218:48-56.
20. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010;84:7064-72.
21. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 2012;130:847-56.
22. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-58.
23. Merkel cell carcinoma. Chapter 30. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
24. Leonard JH, Dash P, Holland P, Kearsley JH, Bell JR. Characterisation of four Merkel cell carcinoma adherent cell lines. Int J Cancer 1995;60:100-7.
25. Ronan SG, Green AD, Shilkaitis A, Huang TS, Das Gupta TK. Merkel cell carcinoma: in vitro and in vivo characteristics of a new cell line. J Am Acad Dermatol 1993;29:715-22. (Pubitemid 23327971)
26. Van Gele M, Leonard JH, Van Roy N, Van Limbergen H, Van Belle S, Cocquyt V, et al. Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. Int J Cancer 2002;101:137-45. (Pubitemid 34970905)
27. Rosen ST, Gould VE, Salwen HR, Herst CV, Le Beau MM, Lee I, et al. Establishment and characterization of a neuroendocrine skin carcinoma cell line. Lab Invest 1987;56:302-12. (Pubitemid 17065350)
28. Duncavage EJ, Zehnbauer BA, Pfeifer JD. Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol 2009;22:516-21.
29. Helmbold P, Lahtz C, Enk A, Herrmann-Trost P, Marsch W, Kutzner H, et al. Frequent occurrence of RASSF1A promoter hypermethylation and Merkel cell polyomavirus in Merkel cell carcinoma. Mol Carcinog 2009;48:903-9.
30. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, et al. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 2008;111:289-97.
31. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009;106:19503-8.
32. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56. (Pubitemid 43898818)
33. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
34. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
35. Kuwamoto S, Higaki H, Kanai K, Iwasaki T, Sano H, Nagata K, et al. Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma. Hum Pathol 2011;42:632-40.
36. Laude HC, Jonchere B, Maubec E, Carlotti A, Marinho E, Couturaud B, et al. Distinct Merkel cell polyomavirus molecular features in tumour and nontumour specimens from patients with Merkel cell carcinoma. PLoS Pathog 2010;6:e1001076.
37. Dworkin AM, Tseng SY, Allain DC, Iwenofu OH, Peters SB, Toland AE. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol 2009;129:2868-74.
38. Teman CJ, Tripp SR, Perkins SL, Duncavage EJ. Merkel cell polyomavirus (MCPyV) in chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Res 2011;35:689-92.
39. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 2009;101:938-45.
40. Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW. Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome. Int J Cancer 2010;127:1493-6.
41. DeCaprio JA. Does detection of Merkel cell polyomavirus in Merkel cell carcinoma provide prognostic information? J Natl Cancer Inst 2009;101:905-7.
42. Deyrup AT, Lee VK, Hill CE, Cheuk W, Toh HC, Kesavan S, et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 2006;30:75-82. (Pubitemid 43740212)
43. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
44. Katano H, Ito H, Suzuki Y, Nakamura T, Sato Y, Tsuji T, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi's sarcoma. J Med Virol 2009;81:1951-8.
45. Lassacher A, Heitzer E, Kerl H, Wolf P. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. J Invest Dermatol 2008;128:1788-96. (Pubitemid 351847382)
46. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in merkel cell carcinoma. Clin Cancer Res 2011;17:4806-13.
47. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:1441-6.
48. Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang CH, et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A 2009;106:16996-7001.
49. Vazquez F, Devreotes P. Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction. Cell Cycle 2006;5:1523-7. (Pubitemid 44091972)
50. Van Gele M, Leonard JH, Van Roy N, Cook AL, De Paepe A, Speleman F. Frequent allelic loss at 10q23 but lowincidence ofPTEN mutations in Merkel cell carcinoma. Int J Cancer 2001;92:409-13. (Pubitemid 32249719)
51. Fernandez-Figueras MT, Puig L, Musulen E, Gilaberte M, Lerma E, Serrano S, et al. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol 2007;20:90-101. (Pubitemid 44967954)
52. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev 2009;9:28-39.
53. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, et al. NVPBEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009;8:2204-10.
54. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
55. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010;20:87-90.
56. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.